Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy (ET) deeply transformed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. Randomized clinical trials suggest that second progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Munzone, E., Pagan, E., Bagnardi, V., Montagna, E., Cancello, G., Dellapasqua, S., Iorfida, M., Mazza, M., Colleoni, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645913/
https://www.ncbi.nlm.nih.gov/pubmed/34864350
http://dx.doi.org/10.1016/j.esmoop.2021.100332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645913/
https://www.ncbi.nlm.nih.gov/pubmed/34864350
http://dx.doi.org/10.1016/j.esmoop.2021.100332

Ejemplares similares